Featured Story | By Nick Paul Taylor Enanta Pharmaceuticals’ bid to treat low-risk respiratory syncytial virus (RSV) patients has gone off the rails. The failure of the phase 2b trial of N-protein inhibitor EDP-938 in the population sent Enanta’s stock to its lowest ebb since 2017 but failed to extinguish the biotech’s belief in the prospect in other settings. read more |
| |
|---|
|
| Sponsored By: ValGenesis Inc. AR-driven hands-free validation isn’t just a futuristic concept. It’s available now, and it has the power to transform the life sciences. Read more. read more |
| |
|---|
|
| Sponsored By: Danaher Corporation The Life Sciences companies at Danaher are setting the template for end-to-end creation of new mRNA medicines, with innovations in plasmid DNA, RNA oligonucleotides, lipid nanoparticles and more. read more |
| |
|---|
|
|  | Webinar: Workplaces Have Changed. How Are You Managing Yours? Wednesday, June 1 | 11am ET / 8am PT Optimizing your diverse spaces, while giving employees an exceptional experience, is more important than ever. Learn how the Connected Workplace for Life Sciences can help you support the full lifecycle of your buildings, spaces, and every asset within them all on one platform. Register now. |
Top Stories By Max Bayer Amgen and deCODE Genetics say the future of their partnership is in the clinic, touting the impact gene hunting has on drug development. The aspirations were relayed at deCODE's belated 25th-anniversary event. read more By Nick Paul Taylor Nanobiotix has joined the ranks of biotechs that are trying to eke out their cash reserves. With its cash down to 70.6 million euros ($74 million) and its phase 3 solid tumor trial still two years away from interim data, the French biotech is enacting a suite of changes intended to save up to 15 million euros a year. read more By Gabrielle Masson Locus Biosciences—a clinical-stage biotech developing a new class of CRISPR-based antibacterial drugs—just closed a $35 million financing round with backing from Johnson & Johnson. read more By Max Bayer Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. read more By James Waldron Inceptor Bio will use proceeds from a $37 million series A round to push its lead CAR-T program into phase 1 trials and set up manufacturing capability in Florida. read more By Gabrielle Masson Pfizer's push for clinical diversity will see it team up with trial site network Headlands Research to break ground on several new research sites in diversely populated areas. read more By James Waldron From Sega to skeletons—Sonic the Hedgehog may have found a new use. But rather than the speedy blue creature beloved of computer gamers, this sonic is a gene that could play a vital role in repairing major bone injuries. read more By Kevin Dunleavy What biopharma companies increased their value the most in the first quarter of this year? The answer might be a surprise—Bayer and AbbVie. Meanwhile, as measured by market cap, COVID-19 vaccine makers BioNTech and Moderna saw their values drop precipitously. read more By Gareth Macdonald People taking part in cancer drug trials at home comply with treatment protocols almost as much as people involved in site-based research do, according to analysis by Clario Research. read more By Angus Liu Scientists have linked chronic inflammation and regulatory T cells together in pinpointing a potential new drug target for colorectal cancer. The findings point to drugs like Amgen and AstraZeneca's newly approved tezepelumab as a possible treatment for the disease. read more By Dave Muoio A new study suggesting fewer mixed-practice internists from 2008 to 2018 raises red flags for care transitions and the supply of outpatient clinicians. read more By Andrea Park After proving that its blood test to measure the level of amyloid plaques in the brain matches up to the results of PET scans in predicting the onset of Alzheimer’s disease, C2N Diagnostics is expanding its slate of Alzheimer’s screening tools. read more Resources Sponsored by: Catalent In this executive summary, we describe the benefits of controlled release, look at how to determine whether a drug is suitable for controlled release, review the application of PBPK modelling in controlled release formulation development and discuss how modified release products can be developed to deliver optimal patient outcomes. Sponsored by: Merit Solutions Quality operations guide your organization through regulatory compliance processes and safeguard your products, processes, and reputation. But your team is capable of so much more. Quality incident data and processes can be a driver of significant business value if shared with other stakeholders. Sponsored by: Blue Matter, strategic consultants in the life sciences Recent trends are driving big changes in Medical Affairs. This paper explores why, and what MA teams can do to stay ahead of the curve. Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. | 
